The manufacturer of the new erectile dysfunction drug, Avanafil, recently posted positive results from the drug’s clinical trials.
Last Tuesday, Vivus, a pharmaceutical company, posted positive results from a trial of its new erectile dysfunction drug that is currently undergoing the review of the US Food and Drug Administration.
Avanafil, the experimental impotence drug, was proved to help 71% of patients to start the sexual intercourse within 15 minutes and after 6 hours after dosing.
In the 80% of cases, the 200-mg dose was sufficient for men suffering from ED, to get and maintain healthy erection.
The results of the clinical trial were published in the Journal of Sexual Medicine.
Commenting on the findings, Irwin Goldstein, the investigator of Avanafil, said: “While PDE-5 inhibitors are currently used as first-line therapy for treatment of erectile dysfunction in the general population, what’s new and novel about avanafil is that it has a fast onset of action and high selectivity.”
The drug will appear in US pharmacies provided it gets the approval from US FDA.









